Search Results
Apr 02, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-immunitybio-inc-of-class-action-lawsuit-and-upcoming-deadlines--ibrx-302732502.htmlSOURCE
More news about: Pomerantz LLP
Apr 01, 2026, 16:07 ET ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing,
More news about: Hagens Berman Sobol Shapiro LLP
Apr 01, 2026, 15:05 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to
More news about: THE ROSEN LAW FIRM, P. A.
Apr 01, 2026, 09:00 ET IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky
Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. (NASDAQ: IBRX) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between January 19, 2026 and March 24, 2026. IBRX shares fell $1.98 per share, or 21%, after the FDA determined that the Company's
More news about: Levi & Korsinsky, LLP
Apr 01, 2026, 01:45 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Mar 31, 2026, 14:17 ET INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"), have until May 26, 2026 to seek appointment
More news about: Robbins Geller Rudman & Dowd LLP
Mar 31, 2026, 09:00 ET IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit -- The Gross Law Firm
March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX).
More news about: The Gross Law Firm
Mar 30, 2026, 15:49 ET ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman
www.hbsslaw.com/investor-fraud/ibrxContact the Firm Now: [email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class
More news about: Hagens Berman Sobol Shapiro LLP
Mar 29, 2026, 08:25 ET IBRX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Mar 27, 2026, 17:30 ET IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm
global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to
More news about: THE ROSEN LAW FIRM, P. A.
Mar 27, 2026, 14:52 ET IBRX INVESTOR ALERT: ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2025, inclusive (the "Class Period"), have until May 26, 2026 to seek appointment
More news about: Robbins Geller Rudman & Dowd LLP
Mar 27, 2026, 09:15 ET Scalable Biotech Manufacturing Unlocks a $14B Market
creating deep, sustainable value across a new class of durable therapy developers, including Avaí Bio (OTCQB: AVAI), ImmunityBio (NASDAQ: IBRX), Fate Therapeutics (NASDAQ: FATE), Fractyl Health (NASDAQ: GUTS), and Moleculin Biotech (NASDAQ: MBRX).
More news about: USA News Group
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Mar 09, 2026, 07:30 ET ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
disease1CULVER CITY, Calif., March 9, 2026 /PRNewswire/ -- ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of its supplemental
More news about: ImmunityBio
Feb 25, 2026, 09:00 ET Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
vaccines[1]. Five companies positioned at the forefront of this expansion include Oncolytics Biotech (NASDAQ: ONCY), ImmunityBio (NASDAQ: IBRX), CRISPR Therapeutics (NASDAQ: CRSP), BioNTech (NASDAQ: BNTX), and Novocure (NASDAQ: NVCR).
More news about: Equity Insider
Feb 19, 2026, 20:06 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Feb 17, 2026, 11:25 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Biotech Inc. (NASDAQ: ONCY), Novocure (NASDAQ: NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ: IBRX), and Nuvation Bio Inc. (NYSE: NUVB) each represent distinct modalities advancing through clinical development in historically treatment-resistant
More news about: Equity Insider
Feb 17, 2026, 11:17 ET New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Biotech Inc. (NASDAQ: ONCY), Novocure (NASDAQ: NVCR), Perspective Therapeutics, Inc. (NYSE-A: CATX), ImmunityBio, Inc. (NASDAQ: IBRX), and Nuvation Bio Inc. (NYSE: NUVB) each represent distinct modalities advancing through clinical development in historically treatment-resistant
More news about: Equity Insider
Feb 12, 2026, 18:56 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 29, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jan 28, 2026, 09:15 ET Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
ONCY), BioNTech (NASDAQ: BNTX), MAIA Biotechnology (NYSE-A: MAIA), Acrivon Therapeutics (NASDAQ: ACRV), and ImmunityBio (NASDAQ: IBRX).
More news about: USA News Group
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
across high-prevalence killers like lung, breast, and pancreatic cancers, led by GT Biopharma, Inc. (NASDAQ: GTBP), ImmunityBio (NASDAQ: IBRX), Erasca, Inc. (NASDAQ: ERAS), NovaBridge Biosciences (NASDQ: NBP), and Coherus Oncology (NASDAQ: CHRS).
More news about: Equity Insider
Sep 16, 2025, 12:29 ET Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Inc. (NASDAQ: ONCY), Anixa Biosciences, Inc. (NASDAQ: ANIX), IceCure Medical Ltd. (NASDAQ: ICCM), ImmunityBio, Inc. (NASDAQ: IBRX), and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).
More news about: USA News Group